Trial Profile

Navigated Laser In Branch Retinal Vein Occlusion Study

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aflibercept (Primary)
Indications Branch retinal vein occlusion; Diabetic macular oedema; Retinal oedema
Focus Therapeutic Use
Acronyms NIRVANA

Most Recent Events

24 Oct 2022 Results (n=41) evaluating if combination treatment of navigated central retinal laser and aflibercept lowered the treatment burden in these patients,published in the Acta Ophthalmologica
18 Apr 2022 Status changed from active, no longer recruiting to completed.
03 Mar 2021 Planned number of patients changed from 60 to 47.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com